Ro is a Healthcare Technology founded in 2017, currently valued at $5B. IPO Status: S-1 Filed in February 2026. IPO Readiness Score: 75/100 (B).
Ro IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Healthcare Technology |
| Stage | Late Stage / Pre-IPO |
| IPO Status | Private |
| Valuation | $5B |
| Total Funding | $1.1B |
| Headquarters | New York, NY |
| IPO Readiness Score | 75/100 |
| Founded | 2017 |
Track Ro IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
Direct-to-patient healthcare platform offering telemedicine, diagnostics, and pharmacy for chronic conditions.
Ro has filed an S-1 registration statement with the SEC in February 2026, signaling active preparation for a public listing. Companies that reach the S-1 filing stage typically price their IPO within 3–6 months of filing, though market conditions, regulatory review, and investor demand can affect the timeline. TechStackIPO monitors all S-1 amendments, pricing updates, and roadshow activity for Ro.
Ro is valued at $5B based on the most recent private market data. The company has raised a total of $1.1B in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Ro pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Ro has an IPO readiness score of 75/100 on TechStackIPO. A high readiness score suggests IPO activity could occur within the next 1–2 years.
Ro's last known private valuation is $5B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
Yes. Ro has filed an S-1 registration statement with the SEC on February 14, 2026.
Ro operates in the Healthcare Technology sector. TechStackIPO tracks multiple Healthcare Technology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Ro against other Healthcare Technology companies using TechStackIPO's comparison tool.
Ro is at the Late Stage / Pre-IPO stage. The company has raised a total of $1.1B in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Ro is headquartered in New York, NY. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.